Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review

被引:3
|
作者
Li, Linlin [1 ]
Huang, Siyuan [1 ]
Qin, Liying [2 ]
Yan, Ningning [1 ]
Shen, Shujing [3 ]
Li, Xingya [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiotherapy, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
NSCLC; epidermal growth factor receptor; L833V/H835L; aumolertinib; case report; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CANCER; OSIMERTINIB; GEFITINIB; AFATINIB; PATIENT; L833V; H835L;
D O I
10.3389/fphar.2023.1257592
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The deletion of exon 19 and the Leu858Arg mutation of exon 21 are the most frequently observed mutations in the epidermal growth factor receptor (EGFR) gene, and patients with these mutations have shown significant benefits from EGFR-tyrosine kinase inhibitors (TKIs). However, there exists a small subgroup of patients with uncommon/rare mutations of EGFR, including compound mutations, which display a high degree of heterogeneity in terms of clinical features and variable sensitivities to EGFR-TKIs. The understanding of these uncommon mutations and their response to targeted therapy is still unclear and requires further investigation.Case presentation: We presented a case of a never-smoking patient with lung adenocarcinoma and brain metastasis. Initially, she received chemotherapy plus immune checkpoint inhibitor as first-line therapy as no EGFR mutations were detected by amplification-refractory mutation system-polymerase chain reaction. However, disease progressed rapidly. Subsequently, next-generation sequencing was carried out and revealed a rare compound mutation, L833V/H835L, in exon 21 of EGFR. As a result, she was switched to second-line therapy with the third-generation TKI aumolertinib, which demonstrated good efficacy. The patient was evaluated for a remarkable progression-free survival of 18 months and an overall survival of 29 months.Conclusion: The present study supports that aumolertinib might be a good treatment option for advanced NSCLC patients with EGFR L833V/H835L mutation, particularly in patients with brain metastasis. Furthermore, conducting a comprehensive screening for gene mutations is crucial in effectively identifying potential oncogenic driver mutations and guiding mutation-targeted therapy decisions in clinical practice.
引用
收藏
页数:8
相关论文
共 39 条
  • [1] A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review
    Yang, Xian
    Yao, Yang
    Zhu, Qing
    HELIYON, 2022, 8 (12)
  • [2] The effectiveness of sequential afatinib and furmonertinib in an advanced lung adenocarcinoma with rare compound EGFR mutation (L833V/H835L)
    Pan, Yanqing
    Yan, Lingxin
    Gu, Yongyao
    Wang, Shaoxi
    Li, Huiling
    Yu, Pengli
    Chen, Quanfang
    ANTI-CANCER DRUGS, 2025, 36 (04) : 355 - 358
  • [3] Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
    Long, Xiang
    Qin, Tian
    Lin, Junhong
    ONCOTARGETS AND THERAPY, 2020, 13 : 10689 - U67
  • [4] Successful intercalating multimodal treatment strategy in a patient with advanced adenocarcinoma of the lung harboring the uncommon complex EGFR mutation L833V/H835L
    Frille, A.
    Saendig, I
    Wirtz, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 92 - 92
  • [5] The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Yuan, Ling-Yan
    Liu, Ke
    Wang, Zhan
    Qin, Wen-Xing
    Zang, Yuan-Sheng
    ONCOTARGETS AND THERAPY, 2018, 11 : 4739 - 4745
  • [6] A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib
    Frega, Stefano
    Conte, PierFranco
    Fassan, Matteo
    Polo, Valentina
    Pasello, Giulia
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) : E63 - E64
  • [7] Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report
    Al-Nusair, Jowan
    Bodiwala, Reesha
    Nwanwene, Kemnasom
    Abdallah, Mahmoud
    Alshal, Mohamed
    Pacioles, Toni
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2024, 12
  • [8] Good Response to Gefitinib in a Lung Adenocarcinoma Harboring a Heterozygous Complex Mutation of L833V and H835L in Epidermal Growth Factor Receptor Gene
    Yang, Tsung-Ying
    Tsai, Chi-Ren
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Lee, Hsien-Ming
    Chang, Gee-Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : E468 - E469
  • [9] Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib
    Smith, Jarrod T.
    Puri, Sonam
    Akerley, Wallace
    CLINICAL LUNG CANCER, 2023, 24 (04) : 360 - 361
  • [10] Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
    Zhou, Bin
    Wang, Yanan
    Liao, Haijiang
    Li, Ben
    MEDICINE, 2022, 101 (33) : E30080